title: Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
abstract: BACKGROUND
  Neoadjuvant hormonotherapy has recently been used for downstaging large or locally advanced (LA) breast cancer in postmenopausal women.
  
  
  METHODS
  A phase II study was conducted in postmenopausal, hormone-receptor (HR) positive, T2-T4 patients, receiving 25 mg/day exemestane for 16 weeks.
  
  
  RESULTS
  Among 42 patients, 57.1% underwent conservative surgery. The clinical objective response rate (ORR) was 73.3%, without progression. A pathological partial response was achieved in 16.7% of the patients. Exemestane significantly reduced the expression of Ki-67 and progesterone receptors (PgR) (p<0.001). A significant decrease in PgR was correlated with clinical ORR (p=0.028). The responders presented higher baseline PgR levels (p=0.017). No relationship was found between ORR and mRNA expression of aromatase or oestrogen receptors beta (ER-beta).
  
  
  CONCLUSIONS
  Neoadjuvant exemestane provided satisfactory efficacy and safety profiles in LA breast cancer. The main biological effects consisted of a reduction in PgR expression for responders and a decrease in Ki-67 expression.
authors: Departments of Medical Oncology, Centre René Huguenin, 35 rue daily, 92210 St-Cloud, France. m.tubiana@stcloud-huguenin.org
authors: Michele
authors: M
authors: Tubiana-Hulin
authors: Veronique
authors: V
authors: Becette
authors: Ivan
authors: I
authors: Bieche
authors: Louis
authors: L
authors: Mauriac
authors: Gilles
authors: G
authors: Romieu
authors: Frederic
authors: F
authors: Bibeau
authors: Gaetan
authors: G
authors: Macgrogan
authors: Hugues
authors: H
authors: Bourgeois
authors: Philippe
authors: P
authors: Chollet
authors: Remy
authors: R
authors: Defrance
authors: Frederique
authors: F
authors: Spyratos
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D047628:Estrogen Receptor alpha / Q000096:biosynthesis / Q000235:genetics; D047629:Estrogen Receptor beta / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis / Q000235:genetics; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017698:Postmenopause; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D019394:Ki-67 Antigen; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; C056516:exemestane